From the Editor
Article first published online: 16 AUG 2010
DOI: 10.1111/j.1365-2125.2010.03756.x
© 2010 The Author. Journal compilation © 2010 The British Pharmacological Society
Issue

British Journal of Clinical Pharmacology
Special Issue: Pharmacoeconomics Theme Issue
Volume 70, Issue 3, page 439, September 2010
Additional Information
How to Cite
Ritter, J.M. (2010), From the Editor. British Journal of Clinical Pharmacology, 70: 439. doi: 10.1111/j.1365-2125.2010.03756.x
Publication History
- Issue published online: 16 AUG 2010
- Article first published online: 16 AUG 2010
In 1988 The Nobel Assembly at the Karolinska Institute decided to award the Nobel Prize in Physiology or Medicine to Sir James Black, jointly with Gertrude Elion and George Hitchings. In their press release they wrote: ‘Sir James W. Black realized the great pharmacotherapeutic potential of receptor blocking drugs and developed in 1964 the first clinically useful beta-receptor blocking drug, propranolol. This type of drug is now being used in the treatment of coronary heart disease (angina pectoris, myocardial infarction) and hypertension. In 1972 Black characterized a new group of histamine receptors, H2-receptors, and subsequently developed the first clinically useful H2-receptorantagonist, cimetidine. A new principle in the treatment of peptic ulcer was thereby introduced.’ The new drugs he invented not only enabled mechanistic discoveries that changed our understanding of physiology and pathophysiology but also changed medical practice to the great benefit of mankind. In the present issue we co-publish with our sister journal BJP, in tribute, an inspirational paper by James Black titled ‘A life in new drug research’, together with an obituary by Alan McGregor.

1365-2125/asset/olbannerleft.gif?v=1&s=e86b92cac3efbbd2e255b9fa97ece9623eac0b54)
1365-2125/asset/olbannerright.gif?v=1&s=6a7c47d290382bf3bc40c62461bc36a371a081bf)